Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Net Income towards Common Stockholders: 2013-2024

Historic Net Income towards Common Stockholders for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$132.1 million.

  • Aclaris Therapeutics' Net Income towards Common Stockholders fell 80.78% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 279.49%. This contributed to the annual value of -$132.1 million for FY2024, which is 49.26% down from last year.
  • As of FY2024, Aclaris Therapeutics' Net Income towards Common Stockholders stood at -$132.1 million, which was down 49.26% from -$88.5 million recorded in FY2023.
  • Aclaris Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $139,000 during FY2020, with a 5-year trough of -$132.1 million in FY2024.
  • In the last 3 years, Aclaris Therapeutics' Net Income towards Common Stockholders had a median value of -$88.5 million in 2023 and averaged -$102.5 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Net Income towards Common Stockholders skyrocketed by 100.29% in 2020 and then tumbled by 65,470.50% in 2021.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Net Income towards Common Stockholders stood at $139,000 in 2020, then tumbled by 65,470.50% to -$90.9 million in 2021, then increased by 4.35% to -$86.9 million in 2022, then dropped by 1.81% to -$88.5 million in 2023, then plummeted by 49.26% to -$132.1 million in 2024.